Scientists at the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust used a drug made from a genetically modified form of herpes simplex — the cold sore virus — to attack tumors in cancer patients' bodies, developing a cutting-edge form of cancer therapy in the process.
